Inhibrx Biosciences, INC 10-Q quarterly reports

Inhibrx Biosciences reported continued progress in its clinical pipeline for ozekibart and INBRX-106, alongside a significant increase in long-term debt and ongoing net losses for the second quarter of 2026.

Inhibrx Biosciences reports Q1 2026 results, highlighting clinical trial advancements for ozekibart and INBRX-106, alongside a strengthened balance sheet through debt financing.

Inhibrx Biosciences announced positive Phase 2 results for ozekibart in chondrosarcoma, planning a Q2 2026 BLA submission, alongside promising interim data for other pipeline assets, despite reporting a net loss for the nine months ended September 30, 2025.

Inhibrx Biosciences reports significantly reduced operating expenses and a new debt facility in Q2 2025, as it awaits crucial clinical trial data for its lead therapeutic candidates later this year.

Inhibrx Biosciences announces its Q1 2025 financial results, showcasing a decrease in operating expenses and providing updates on its clinical development programs.

Inhibrx Biosciences reports its Q3 2024 results, highlighting a significant gain from a merger and providing updates on its clinical pipeline following a strategic separation.

Inhibrx Biosciences completed its spin-off and merger, reporting a significant gain from the transaction while continuing to advance its clinical pipeline.